8-K Announcements
6Material company update
May 15, 2026·SEC
Material company update
Mar 18, 2026·SEC
Material company update
Feb 2, 2026·SEC
ProKidney Corp.(PROK)Earnings, Financials & Key Ratios
PROK•NASDAQ
Price updated Jun 19, 2026
AboutProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.Show more
- Revenue$893K+1075.0%
- EBITDA-$158M+11.1%
- Net Income-$69M-12.7%
- EPS (Diluted)-0.52+16.1%
- Gross Margin100%
- EBITDA Margin-17741.55%+92.4%
- Operating Margin-18477.83%+92.4%
- Net Margin-7725.2%+90.4%
- ROE-19.64%-27.3%
PROK Key Insights
ProKidney Corp. (PROK) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓High quality earnings: Operating CF exceeds net income
- ✓Trading at only 0.8x book value
✗Weaknesses
- ✗Profits declining 20.9% over 5 years
- ✗Weak Piotroski F-Score: 1/9
- ✗Negative free cash flow
- ✗Shares diluted 36.8% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when PROK posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PROK Price & Volume
ProKidney Corp. (PROK) stock price & volume — 10-year historical chart
Loading chart...
PROK Growth Metrics
ProKidney Corp. (PROK) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM190.52%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-9.36%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM8.33%
Return on Capital
10 Years-160.97%
5 Years-92.89%
3 Years-41.99%
Last Year-46.5%
PROK Recent Earnings
ProKidney Corp. (PROK) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 3/12 qtrs (100%)
Q2 2026Latest
May 15, 2026Metric
Actual
Est
EPS
$0.14-7.7%
$0.13
Rev
$226,000+125.4%
$100,250
Q2 2026
Mar 18, 2026Metric
Actual
Est
EPS
$0.14+12.5%
$0.16
Rev
$223,000+37066.7%
$600
Q4 2025
Nov 10, 2025Metric
Actual
Est
EPS
$0.12+0.0%
$0.12
Rev
$217,000
—
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$0.13+7.1%
$0.14
Rev
$221,000+399.4%
$44,250
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $0.14vs $0.13-7.7% | $226,000vs $100,250+125.4% |
| Q2 2026 | Mar 18, 2026 | $0.14vs $0.16+12.5% | $223,000vs $600+37066.7% |
| Q4 2025 | Nov 10, 2025 | $0.12vs $0.12+0.0% | $217,000 |
| Q3 2025 | Aug 12, 2025 | $0.13vs $0.14+7.1% | $221,000vs $44,250+399.4% |
Based on last 12 quarters of dataView full earnings history →
PROK Peer Comparison
ProKidney Corp. (PROK) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RCKT | 365.8M | 3.35 | -1.67 | -70.79% | 0.09 | |||
 FATE | 243.61M | 2.09 | -1.82 | -51.24% | -20.57% | -58.89% | 0.38 | |
 NTLA | 1.76B | 15.67 | -4.11 | 16.92% | -5.97% | -57.27% | 0.14 | |
 BEAM | 3.51B | 34.14 | -42.15 | 120.01% | -49.17% | -5.89% | 0.24 | |
 RGEN | 7.45B | 132.02 | 153.51 | 16.36% | 6.73% | 2.46% | 0.33 | |
 ALLO | 487.74M | 2.00 | -2.30 | -100% | -56.45% | 0.26 | ||
 SANA | 876.62M | 3.15 | -3.28 | -161.87% | 0.49 | |||
 ILMN | 24.6B | 161.93 | 29.71 | -0.78% | 19.43% | 32.84% | 0.94 |
Compare PROK vs Peers
ProKidney Corp. (PROK) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PROK Income Statement
ProKidney Corp. (PROK) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 76K | 893K | 889K |
Revenue Growth % | - | - | - | - | - | - | 1075% | 190.52% |
Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.88M |
COGS % of Revenue | - | - | - | - | - | - | - | - |
Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 76K▲ 0% | 893K▲ 1075.0% | -2M▲ 0% |
Gross Margin % | - | - | - | - | - | 100% | 100% | -224.41% |
Gross Profit Growth % | - | - | - | - | - | - | 1075% | - |
Operating Expenses | 79.38M | 27.02M | 55.11M | 153.01M | 151.52M | 183.75M | 165.9M | 166.56M |
OpEx % of Revenue | - | - | - | - | - | 241778.95% | 18577.83% | - |
Selling, General & Admin | 4.16M | 5.98M | 8.86M | 70.94M | 44.81M | 56.08M | 51.78M | 43.56M |
SG&A % of Revenue | - | - | - | - | - | 73794.74% | 5798.1% | - |
Research & Development | 75.22M | 21.04M | 46.26M | 82.07M | 106.71M | 127.67M | 114.12M | 120.7M |
R&D % of Revenue | - | - | - | - | - | 167984.21% | 12779.73% | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating Income | -79.38M▲ 0% | -27.02M▲ 66.0% | -55.11M▼ 103.9% | -153.01M▼ 177.6% | -151.52M▲ 1.0% | -183.68M▼ 21.2% | -165.01M▲ 10.2% | -168.55M▲ 0% |
Operating Margin % | - | - | - | - | - | -241678.95% | -18477.83% | -18959.73% |
Operating Income Growth % | - | 65.96% | -103.93% | -177.64% | 0.97% | -21.22% | 10.16% | - |
EBITDA | -78.51M | -26.06M | -53.13M | -149.97M | -147.67M | -178.24M | -158.43M | -162.53M |
EBITDA Margin % | - | - | - | - | - | -234531.58% | -17741.55% | -18282.34% |
EBITDA Growth % | - | 66.81% | -103.86% | -182.29% | 1.54% | -20.71% | 11.12% | 9.23% |
D&A (Non-Cash Add-back) | 867K | 964K | 1.98M | 3.04M | 3.85M | 5.43M | 6.58M | 6.02M |
EBIT | -19.16M | -27.02M | -55.11M | -147.02M | -129.44M | -163.92M | -151.19M | -161.7M |
Net Interest Income | 126 | 43K | 2K | 5.77M | 22.07M | 19.74M | 13.81M | 12.09M |
Interest Income | 126 | 43K | 2K | 5.98M | 22.08M | 19.75M | 13.81M | 12.11M |
Interest Expense | 0 | 0 | 0 | 215K | 12K | 9K | 4K | 19K |
Other Income/Expense | 126K | 43K | 2K | 5.77M | 22.07M | 19.74M | 13.81M | 12.09M |
Pretax Income | -79.25M▲ 0% | -26.98M▲ 66.0% | -55.11M▼ 104.2% | -147.24M▼ 167.2% | -129.45M▲ 12.1% | -163.93M▼ 26.6% | -151.2M▲ 7.8% | -156.46M▲ 0% |
Pretax Margin % | - | - | - | - | - | -215701.32% | -16931.47% | -17599.33% |
Income Tax | 361K | -232K | 38K | 896K | 6M | -598K | 414K | -20.21M |
Effective Tax Rate % | -0.46% | 0.86% | -0.07% | -0.61% | -4.63% | 0.36% | -0.27% | 12.92% |
Net Income | -79.61M▲ 0% | -26.75M▲ 66.4% | -55.15M▼ 106.2% | -108.03M▼ 95.9% | -35.47M▲ 67.2% | -61.19M▼ 72.5% | -68.99M▼ 12.7% | -74.84M▲ 0% |
Net Margin % | - | - | - | - | - | -80507.89% | -7725.2% | -8418% |
Net Income Growth % | - | 66.4% | -106.16% | -95.9% | 67.17% | -72.51% | -12.75% | -9.36% |
Net Income (Continuing) | -79.61M | -26.75M | -55.15M | -148.13M | -135.45M | -163.34M | -151.61M | -136.24M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 1.6B | 1.49B | 1.4B | 1.31B | 1.29B |
EPS (Diluted) | -1.01▲ 0% | -0.14▲ 86.1% | -1.73▼ 1135.7% | -1.76▼ 1.7% | -0.57▲ 67.6% | -0.62▼ 8.8% | -0.52▲ 16.1% | -0.53▲ 0% |
EPS Growth % | - | 86.14% | -1135.71% | -1.73% | 67.61% | -8.77% | 16.13% | 8.33% |
EPS (Basic) | -1.01 | -0.14 | -1.73 | -1.76 | -0.57 | -0.62 | -0.52 | - |
Diluted Shares Outstanding | 78.53M | 186.5M | 31.89M | 61.54M | 61.71M | 97.92M | 133.94M | 141.93M |
Basic Shares Outstanding | 78.53M | 186.5M | 31.89M | 61.54M | 61.71M | 97.92M | 133.94M | 141.93M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - |
PROK Balance Sheet
ProKidney Corp. (PROK) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Total Current Assets | 15.42M | 5.58M | 27.27M | 504.72M | 374.15M | 395.88M | 280.68M | 234.9M |
Cash & Short-Term Investments | 15.23M | 4.58M | 20.56M | 490.25M | 362.95M | 358.29M | 270.02M | 224.94M |
Cash Only | 15.23M | 4.58M | 20.56M | 490.25M | 60.65M | 99.12M | 108.54M | 101.89M |
Short-Term Investments | 0 | 0 | 0 | 0 | 302.3M | 259.17M | 161.48M | 123.05M |
Accounts Receivable | 0 | 0 | 0 | 0 | 1.38M | 2.45M | 1.13M | 1.03M |
Days Sales Outstanding | - | - | - | - | - | 11.75K | 460.64 | 530.77 |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 52K | 25K | 1.38M | 9K | 19.45M | 9.54M | 1.79M |
Total Non-Current Assets | 4.18M | 11.12M | 13.03M | 13.28M | 46.41M | 45.19M | 54.9M | 57.88M |
Property, Plant & Equipment | 3.33M | 10.47M | 12.6M | 13.06M | 46.41M | 45.19M | 54.9M | 57.88M |
Fixed Asset Turnover | - | - | - | - | - | 0.00x | 0.02x | 0.02x |
Goodwill | 0 | 641.36K | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 857K | 642 | 428K | 213K | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Assets | 19.61M▲ 0% | 16.7M▼ 14.8% | 40.3M▲ 141.3% | 518M▲ 1185.4% | 420.55M▼ 18.8% | 441.07M▲ 4.9% | 335.57M▼ 23.9% | 292.78M▲ 0% |
Asset Turnover | - | - | - | - | - | 0.00x | 0.00x | 0.00x |
Asset Growth % | - | -14.83% | 141.31% | 1185.41% | -18.81% | 4.88% | -23.92% | -103.21% |
Total Current Liabilities | 2.71M | 5.5M | 12.31M | 10.87M | 25.04M | 36.22M | 30.74M | 25.93M |
Accounts Payable | 480K | 781K | 2.83M | 3.04M | 5.1M | 3.63M | 940K | 2.59M |
Days Payables Outstanding | - | - | - | - | - | - | - | 250.49 |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.11M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 355K | 1.71M | 0 | 0 | 7.52M | 11.45M | 29.8M | 17.67M |
Current Ratio | 5.68x | 1.02x | 2.21x | 46.42x | 14.94x | 10.93x | 9.13x | 9.06x |
Quick Ratio | 5.68x | 1.02x | 2.21x | 46.42x | 14.94x | 10.93x | 9.13x | 9.06x |
Cash Conversion Cycle | - | - | - | - | - | - | - | 280.27 |
Total Non-Current Liabilities | 1.01M | 1.33M | 1.07M | 2.18M | 4.18M | 3.22M | 4.04M | 3.75M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 1.01M | 1.33M | 1.07M | 1.91M | 3.61M | 2.47M | 2.96M | 12.4M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 278K | 568K | 748K | 1.07M | 1.07M |
Total Liabilities | 3.72M | 6.84M | 13.38M | 13.06M | 29.22M | 39.44M | 34.78M | 29.68M |
Total Debt | 1.11M | 1.56M | 1.33M | 2.4M | 4.41M | 3.24M | 2.96M | 3.78M |
Net Debt | -14.11M | -3.02M | -19.22M | -487.85M | -56.24M | -95.88M | -105.57M | -98.11M |
Debt / Equity | 0.07x | 0.16x | 0.05x | 0.00x | 0.01x | 0.01x | 0.01x | 0.01x |
Debt / EBITDA | - | - | - | - | - | - | - | -0.02x |
Net Debt / EBITDA | - | - | - | - | - | - | - | 0.60x |
Interest Coverage | - | - | - | -683.83x | -10786.58x | -18213.78x | -37798.50x | -8510.58x |
Total Equity | 15.88M▲ 0% | 9.86M▼ 37.9% | 26.92M▲ 172.9% | 504.94M▲ 1775.9% | 391.34M▼ 22.5% | 401.64M▲ 2.6% | 300.79M▼ 25.1% | 263.1M▲ 0% |
Equity Growth % | - | -37.9% | 172.88% | 1775.91% | -22.5% | 2.63% | -25.11% | -110.35% |
Book Value per Share | 0.20 | 0.05 | 0.84 | 8.21 | 6.34 | 4.10 | 2.25 | 1.85 |
Total Shareholders' Equity | 15.88M | 9.86M | 26.92M | -1.1B | -1.1B | -994.95M | -1.01B | -1.02B |
Common Stock | 95.5M | 116.23M | 188.43M | 24K | 23K | 29K | 30K | 30K |
Retained Earnings | -79.61M | -106.36M | -161.51M | -1.1B | -1.14B | -1.2B | -1.27B | -1.29B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 | 0 | 130K | 130K | 56K | -53K |
Minority Interest | 0 | 0 | 0 | 1.6B | 1.49B | 1.4B | 1.31B | 1.29B |
PROK Cash Flow Statement
ProKidney Corp. (PROK) cash flow — operating, investing & free cash flow history
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Cash from Operations | -76.81K | -25.18M | -50.3M | -77.09M | -90.07M | -126.35M | -120.12M | -132.21M |
Operating CF Margin % | - | - | - | - | - | -166251.32% | -13450.95% | - |
Operating CF Growth % | - | -32685.2% | -99.75% | -53.26% | -16.84% | -40.28% | 4.93% | -48.37% |
Net Income | -79.61K | -26.75M | -55.15M | -148.13M | -135.45M | -163.34M | -151.61M | -74.84M |
Depreciation & Amortization | 867 | 964K | 1.98M | 3.04M | 3.85M | 5.43M | 6.58M | 6.63M |
Stock-Based Compensation | 498 | 730K | 699K | 74.47M | 30.85M | 29.37M | 25.34M | 17.19M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 1.56K | 0 | 0 | 0 | -6M | -1.78M | -1.7M | -13.87M |
Working Capital Changes | -115 | -126K | 2.16M | -6.46M | 16.67M | 3.96M | 1.28M | -5.26M |
Change in Receivables | 0 | 0 | 0 | 0 | -1.38M | -1.07M | 1.32M | 182K |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 0 | 683K | 5K | 494K | 11.64M | 11.59M | -5.92M | -6.03M |
Cash from Investing | -2.97K | -5.46M | -5.19M | -1.74M | -329.98M | 20.41M | 103.97M | 110.5M |
Capital Expenditures | -1.3K | -5.46M | -5.19M | -1.85M | -34.2M | -29.51M | -15.2M | -17.85M |
CapEx % of Revenue | - | - | - | - | - | 38827.63% | 1701.68% | 2007.42% |
Acquisitions | -1.66K | 0 | 1K | 108K | 0 | 0 | 18.21M | 18.21M |
Investments | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 34.22M |
Cash from Financing | 20K | 19.99M | 71.47M | 548.52M | -9.55M | 144.41M | 25.57M | 25.8M |
Debt Issued (Net) | 0 | -11K | -30K | -32K | -52K | -54K | -26K | -17K |
Equity Issued (Net) | 0 | 0 | 71.5M | 6.05M | -9.5M | 144.32M | 25.59M | 17.86M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | -9.5M | 0 | 0 | 0 |
Other Financing | 20K | 20M | 0 | 542.5M | 0 | 140K | 0 | 7.96M |
Net Change in Cash | 15.23K▲ 0% | -10.65M▼ 70033.0% | 15.98M▲ 250.1% | 469.69M▲ 2839.3% | -429.6M▼ 191.5% | 38.47M▲ 109.0% | 9.42M▼ 75.5% | 4.09M▲ 0% |
Free Cash Flow | -78.11K▲ 0% | -30.64M▼ 39122.4% | -55.49M▼ 81.1% | -78.94M▼ 42.2% | -124.27M▼ 57.4% | -155.86M▼ 25.4% | -135.31M▲ 13.2% | -150.06M▲ 0% |
FCF Margin % | - | - | - | - | - | -205078.95% | -15152.63% | -16879.08% |
FCF Growth % | - | -39122.39% | -81.12% | -42.25% | -57.43% | -25.42% | 13.18% | 0.61% |
FCF per Share | -0.00 | -0.16 | -1.74 | -1.28 | -2.01 | -1.59 | -1.01 | -1.06 |
FCF Conversion (FCF/Net Income) | 0.00x | 0.94x | 0.91x | 0.71x | 2.54x | 2.07x | 1.74x | 2.01x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 145K | 68K | 1.95M | 2.86M | 73K | 0 | 0 |
PROK Key Ratios
ProKidney Corp. (PROK) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -207.78% | -299.86% | -40.62% | -7.91% | -15.43% | -19.64% | -24.5% |
Return on Invested Capital (ROIC) | -470.58% | -568.61% | -926.23% | -64.53% | -42.99% | -49.41% | -59.74% |
Gross Margin | - | - | - | - | 100% | 100% | -224.41% |
Net Margin | - | - | - | - | -80507.89% | -7725.2% | -8418% |
Debt / Equity | 0.16x | 0.05x | 0.00x | 0.01x | 0.01x | 0.01x | 0.01x |
Interest Coverage | - | - | -683.83x | -10786.58x | -18213.78x | -37798.50x | -8510.58x |
FCF Conversion | 0.94x | 0.91x | 0.71x | 2.54x | 2.07x | 1.74x | 2.01x |
Revenue Growth | - | - | - | - | - | 1075% | 190.52% |
Related:PROK Dividend History·PROK Revenue History·PROK Price History·PROK P/E History·PROK Financial Ratios·PROK Institutional Holders
PROK SEC Filings & Documents
ProKidney Corp. (PROK) SEC filings — annual & quarterly reports (10-K, 10-Q)
PROK Frequently Asked Questions
ProKidney Corp. (PROK) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
ProKidney Corp. (PROK) reported $0.9M in revenue for fiscal year 2025.
ProKidney Corp. (PROK) grew revenue by 1075.0% over the past year. This is strong growth.
ProKidney Corp. (PROK) reported a net loss of $74.8M for fiscal year 2025.
Dividend & Returns
ProKidney Corp. (PROK) has a return on equity (ROE) of -19.6%. Negative ROE indicates the company is unprofitable.
ProKidney Corp. (PROK) had negative free cash flow of $150.1M in fiscal year 2025, likely due to heavy capital investments.